Intec Pharma (NTEC) Receives European Patent Related to Carbidopa/Levodopa Accordion Pill
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Intec Pharma Ltd. (Nasdaq: NTEC) announces that the European Patent Office has granted a European patent for an Accordion Pill containing certain drugs, including the combination Carbidopa and Levodopa. The patent, granted under No. 2276473, is titled “Gastroretentive Drug Delivery for Carbidopa / Levodopa” and is currently scheduled to remain in force until April 2029. The patent belongs to the company’s IN-7 patent family, which already includes patents granted in the U.S.
“We continue to protect and build upon our solid intellectual property position for our versatile Accordion Pill platform technology,” noted Zeev Weiss, Chief Executive Officer of Intec Pharma. “This European patent is important as it protects key elements of our platform technology, and provides patent protection in Europe for our leading product, the Accordion Pill Carbidopa / Levodopa, currently in a global Phase III clinical trial in advanced Parkinson's disease.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY), Ono Enter Settlement and License Agreement with Merck (MRK) to Resolve PD-1 Antibody Patent Litigation
- Rennova Health (RNVA) Says Genomas Subsidiary Granted Patent
- Minerva Neurosciences (NERV) Reports Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!